Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

High levels of immunosuppressant may lead to tumor recurrence

25.04.2005


A new study on the incidence of liver cancer after transplant found that high levels of the immunosuppressant cyclosporine favored tumor recurrence and identified blood levels of the drug that should not be exceeded. Lower levels of cyclosporine levels did not affect rejection rates.

The results of this study appear in the May 2005 issue of Liver Transplantation, the official journal of the American Association for the Study of Liver Diseases (AASLD) and the International Liver Transplantation Society (ILTS). The journal is published on behalf of the societies by John Wiley & Sons, Inc. and is available online via Wiley InterScience at www.interscience.wiley.com/journal/livertransplantation

Hepatocellular carcinoma (HCC, a type of liver cancer) occurs frequently in patients with chronic liver disease who are listed for liver transplants. However, the immunosuppressants necessary to prevent rejection can accelerate tumor growth, and the incidence of tumor recurrence is high.



Because of this, strict selection criteria of patients with HCC has limited their access to transplants, yet the role of immunosuprressants in tumor growth has not been well established. In a previous study, the authors demonstrated a close relationship between the amount of cyclosporine and tumor recurrence in liver transplant patients.

The current study further examines this association and identifies possible strategies to avoid it.

Led by Marco Vivarelli of the department of surgery and transplantation at the University of Bologna, Italy, the study examined 70 patients who took cyclosporine as the main immunosuppressant following liver transplants between 1991 and 2002. The cyclosporine dosage was determined by the clinician in charge based on clinical and biochemical indications, but without regard to blood levels achieved by the drug after it was administered. HCC recurred in 7 of the patients between 2 and 40 months after transplant. The researchers found that the absence of recurrence was significantly related to blood levels of cyclosporine, which were higher in patients whose tumors recurred. Other factors, such as recipient sex, underlying liver disease, or the use of cyclosporine with other immunosuppressants or steroids did not affect tumor recurrence.

"We provide here further evidence on the key role of immunosuppression in tumor recurrence after liver transplantation; in particular, we recommend that in those patients transplanted for hepatocellular carcinoma who receive CsA–based [cyclosporine] immunosuppression the exposure to the drug should not exceed the daily blood levels that we identified," the authors state. Since higher and lower levels of cyclosporine did not affect rejection rates, they suggest that minimum dosage levels of the drug can be safely used. In addition, they suggest that immunosuppressive schedules might be tailored to individual patients based on the biology of their tumors, keeping in mind that high-risk patients would probably benefit from keeping cyclosporine levels as low as possible. They conclude that new immunosuppressant drugs shown to have anti-cancer effects are particularly promising for HCC patients.

David Greenberg | EurekAlert!
Further information:
http://www.wiley.com

More articles from Studies and Analyses:

nachricht Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT

nachricht Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

IHP presents the fastest silicon-based transistor in the world

05.12.2016 | Power and Electrical Engineering

InLight study: insights into chemical processes using light

05.12.2016 | Materials Sciences

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>